GMP Cell Therapy Consumables Market to Reach USD 114.5 Million by 2035

According to analysts at Vantage Market Research, the Global GMP cell therapy consumables Market size is worth USD 15.05 Million in 2024 and is projected to reach USD 114.4 Million by 2035, growing at a CAGR (Compound Annual Growth Rate) of 28.9% from 2024 to 2035. Key trends of market include technological advancements, personalized medicine and expanding applications.

Market Overview

The GMP Cell therapy consumables market is driven by rising demand for advanced therapies, increasing investments in cell therapy research, and a growing prevalence of chronic diseases that require innovative treatment options. Moreover, advancements in technology and the expansion of manufacturing capabilities are anticipated to further boost market growth. Drug discovery is an substantial journey that encompasses several stages, including initial discovery, preclinical trials, clinical studies, and regulatory approval. This complex process heavily relies on cell therapy consumables to obtain optimal results. The World Health Organization reported approximately 10 million cancer-related deaths in 2020, with the most prevalent types being breast, lung, colon, rectal, and prostate cancers.

Biotech and pharmaceutical companies are increasing their R&D expenditures to develop innovative cell-based therapies for a wide range of medical conditions. The flourishing fields of stem cell research and regenerative medicine are also attracting substantial investments from both public and private sectors. In response to the growing demand from cell therapy clinical trials and research projects, leading consumable suppliers are expanding their product portfolios and production capacities. This dynamic is further evidenced by the increasing number of collaborations between consumable suppliers and cell therapy developers.

Sony Introduces New Closed Cell Isolation System CGX10 for use in Production of Advanced Cell Therapy Products

• In January 2022, Sony Corporation ("Sony") today introduced a new Cell Isolation System, CGX10, which sorts cells at high speed and high purity in a closed system. The CGX10's design enables sorting of cells in a manner that is designed to be closed off from the outside environment, making it possible to analyze and isolate cells while maintaining a sterile state

Key Takeaways from the Report

• In 2024, North America dominated the market with 42.60% market share. The market is driven by increasing demand for cell therapies, the surging use of GMP cell therapy consumables, and rising research efforts in drug discoveries
• Based on the Product Type, the Cell Culture media and Supplements category accounted for significant market share for 41.40% in 2024. The segment play a crucial role in tissue engineering, regenerative medicine research, and the production of downstream cell therapies
• In 2024, Based on Cell Type, Stem Cells dominated the market share of 41.80%. Stem cell therapies, utilizing sources like mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs)
• Based on the Application, the Oncology category accounted for significant market share of 44.50% in 2024. The segment is driven by extensive global research efforts and the burgeoning field of cell-based cancer treatments
• By End Users, Hospitals and Clinics dominated the largest market share. The segment is driven by increasing clinical trials in hospitals due to high prevalence of chronic diseases, rising clinical studies and research efforts

Top Companies

• Thermo Fisher Scientific Inc
• Lonza Group
• Merck KGaA
• Corning Inc
• Sartorius AG
• Danaher Corporation
• GE Healthcare
• HiMedia Laboratories
• Beckman Coulter Inc
• Avantor Inc
• Bio-Techne Corporation
• Stemcells Technologies Inc

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Thermo Fisher Scientific Launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to Enhance Cell Therapy Development and Production

• In April 2024, Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8 (CTS Detachable Dynabeads). These latest products expand on Thermo Fisher’s CTS Detachable Dynabeads platform, which represents a new generation of cell therapy isolation and/or activation products that prioritize cell quality while also creating greater workflow control. Ultimately, these products can help customers maximize the potential of their therapies to save more lives